2/28/2013

China's State Food and Drug Administration has announced plans for wide-ranging changes in its drug regulatory process. The plan will foster research and development through a more favorable regulatory environment; update the national strategy for generic drugs; boost the quality of pharmaceutical clinical trials and how they are managed; and encourage the creation of more pediatric pharmaceuticals.

Full Story:
Regulatory Focus

Related Summaries